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Depressive disorders are currently treated with drugs that mainly act by increasing brain monoamine 
levels. These drugs usually exhibit a delayed onset to achieve a full antidepressant action (2–4 
weeks). It has been suggested that RS67333, a 5-HT4 receptor partial agonist, induces both, 
antidepressant-like responses and neuroplasticity-associated changes with a short onset of action (3-7 
days). This opens a new strategy for developing faster-acting antidepressant drugs, though their 
mechanism of action has not been fully elucidated. Recent data suggest the involvement of 
neuroproliferative/neuroplastic signalling pathways in the mechanisms of the antidepressant action. 
The objective of the present study was to analyze, by real time PCR, the time course of expression of 
plasticity-related genes induced by both RS67333 and venlafaxine (a serotonin norepinephrine 
reuptake inhibitor) in organotypic hippocampal slice cultures obtained from P7 Sprague Dawley male 
rats (Stoppini L, Buchs P.A, Muller D. Journal of Neuroscience Methods, 37: 173-182,1991). 
In each experiment, slices from 4 animals were pooled and used to evaluate the effect of each drug 
(each analysis was run 3 times). The slices were exposed to 1 uM of either RS67333 or venlafaxine 
dissolved in culture medium for 1, 3 or 7 days. We tested mRNA levels of  Wnt/-catenin pathway 
related genes: -catenin gene (Ctnnb1), Axin1, Axin2, Myc, as well as Wnt/-catenin-nonrelated 
genes:  Notch1 and Ccnd1. Relative expression levels were expressed as fold of change using the 2-
Ct method with GAPDH as internal reference. 
RS67333 up-regulated Ccnd1 (9.22±0.46; 27.58±0.92; 3.74±0.77; p<0.05 respectively for 1, 3 and 7 
days) and Notch1 (11.50±0.65; 48.41±0.98; 14.19±0.71; p< 0.05 respectively for 1, 3 and 7 days), but 
not the Wnt/-catenin related genes  Ctnnb1, Axin, or Myc. Moreover, venlafaxine up-regulated Wnt/-
catenin genes such as: Ctnnb1 (3.80±0.16; 13.16±0.50; 4.92±0.41;p< 0.01 respectively for 1, 3 and 7 
days), Axin1 (4.50±0.13;p< 0.01 at 1 day); Axin2 (5.06±0.36;p< 0.001 after 3 days), Myc (4.96±0.44; 
1.20±0.43;p< 0.01, after 3 and 7 days), but not Ccnd1 and Notch1 genes expression. One way 
analysis of variance (ANOVA) showed a significant  treatment effect between venlafaxine and 
RS67333 for  Ctnnb1 (F: 15.,02 and F:47.72; p<0.001 respectively at 3 and 7 days), Axin1 (F: 14.34; 
p<0.05, and F: 12.09; p<0.01 respectively at 1 and 7 days), Axin2 (F: 20.75; p<0.01 and F: 34.50, 
p<0.001 respectively at 1 and 3  days), Myc (F: 24.48; p<0.01 and F: 66.75; p<0.001 respectively at 1 
and 3 days), Notch1 (F: 290.40; F: 1373.60 and F: 235.53 , p<0.001respectively at 1, 3 and 7 days) 
and Ccnd1 (F: 171.98 and F: 28.59; p<0.001 respectively at 3 and 7 days). 
Our results show a differential gene expression profile of venlafaxine and RS67333 upon 
neuroplastic/neuroproliferative pathways: venlafaxine increases mRNA expression of the Wnt pathway 
genes whereas RS67333 increases expression of Ccnd1 and Notch1 genes. This drug-dependent 
regulation of neuroplasticity may account for the different onset of the antidepressant like-action of 
venlafaxine and RS67333. 
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